Picture of Theranexus SA logo

ALTHX Theranexus SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+2.08%
3m-4.45%
6m-19.03%
1yr-31.92%
Volume Change (%)
10d/3m-14.89%
Price vs... (%)
52w High-66.98%
50d MA+8.95%
200d MA-5.13%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-118.67%
Return on Equity-118.33%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Theranexus SA EPS forecast chart

Profile Summary

Theranexus SA is a France-based company engaged in the healthcare industry. The Company is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The Company's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
January 2nd, 2013
Public Since
October 30th, 2017
No. of Employees
19
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
5,346,213
Blurred out image of a map
Address
60, LYON, 69008
Web
https://www.theranexus.com/
Phone
+33 188897031
Auditors
Ernst & Young et Autres

ALTHX Share Price Performance

Upcoming Events for ALTHX

Full Year 2023 Theranexus SA Earnings Release

Q1 2024 Theranexus SA Cashflow Reports

Theranexus SA Annual Shareholders Meeting

Theranexus SA Ordinary Shareholders Meeting

Q2 2024 Theranexus SA Cashflow Reports

Half Year 2024 Theranexus SA Earnings Release

Similar to ALTHX

Picture of Abionyx Pharma SA logo

Abionyx Pharma SA

fr flag iconEuronext - Paris

Picture of Abivax SA logo

Abivax SA

fr flag iconEuronext - Paris

Picture of Acticor Biotech SA logo

Acticor Biotech SA

fr flag iconEuronext - Paris

Picture of Adocia SA logo

Adocia SA

fr flag iconEuronext - Paris

Picture of Biophytis SA logo

Biophytis SA

fr flag iconEuronext - Paris

FAQ